NVZMY
Novozymes A/S ADROTCPK - Current
1d
5d
1m
6m
1y
5y
10y
Advanced Chart
  • Thu, May 19, 11:48 AM
    • A Monsanto (MON +4.9%) takeover by Bayer is considered "relatively unlikely" by Jefferies analyst Laurence Alexander, as he expects MON to object to the offer given its conviction in its R&D pipeline and longer-term competitive advantages.
    • Alexander thinks shares of Syngenta (SYT -0.5%) and DuPont (DD -0.7%) could be pressured as regulatory scrutiny likely would intensify if MON gets acquired, and BASF (OTCQX:BASFY -1.4%) could fall on investor concerns of a potential counter-bid.
    • But the analyst sees a potential MON takeover as positive for shares of Novozymes (OTCPK:NVZMY -0.1%) and FMC Corp. (FMC -0.7%), as "a further roll-up of 'specialty generic' agrichemical assets could entice capital, and FMC would be a plausible anchor for such an attempt."
    • Jefferies rates MON as a Hold with a $95 price target.
    • Now read Bayer investor "deeply concerned" about move for Monsanto
    | Thu, May 19, 11:48 AM | 8 Comments